We have compiled a comprehensive review of all the presentations from the conference, with the key points and our expert insight, for you to download, for free. A full list of events and catalysts that were announced or updated during the conference is included in this report.
Key highlights include:
• The meeting kicked off with the blockbuster announcement that Takeda will acquire Ariad (ARIA) and its oncology portfolio for approximately $5.2b. In March 2016, Takeda announced its strategic roadmap where it placed the oncology, gastroenterology, and central nervous system (CNS) franchises as its top R&D priority moving forward.
• Merck (MRK) released a surprising disclosure that it had filed an sBLA for Keytruda in combination with chemotherapy for first-line NSCLC. The filing was surprising in its reliance on the Phase I/II KEYNOTE-021 study rather than the larger Phase III ‘189 study already ongoing.
• Surprisingly, the new CEO of Biogen (BIIB) spent little time discussing any potential differentiators for aducanumab in Alzheimer’s disease following the high-profile failure of LLY’s solanezumab.
• Intra-Cellular Therapies (ITCI) provided an update on its expected meeting with FDA regarding Lumateperone (ITI-007) for the treatment of schizophrenia, but was surprisingly quiet on the Phase III development of ITI-007 for the treatment of agitation in patients with dementia including Alzheimer’s disease.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: